Allegion PLC vs BridgeBio Pharma Inc — how do they compare? Allegion PLC trades at $168.66 (market cap $14.32B), while BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B). The key difference: Allegion PLC and BridgeBio Pharma Inc are close in size by market cap, and Allegion PLC pays a 1.26% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| ALLE | BBIO | |
|---|---|---|
Market Cap | $14.32B | $16.36B |
Sector | Industrials | Health |
52-Week High | $179.77 | $90.17 |
52-Week Low | $125.65 | $47.29 |
Enterprise Value | $16.03B | $18.14B |
Dividend Yield | 1.26% | — |
Trailing returns across standard periods
Latest headlines on both assets
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →